Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Recent reports of case series support the efficacy and safety of topical imiquimod in the treatment of periocular skin tumours.1 2 Cryosurgery is an established ‘non-surgical’ treatment modality for these tumours, particularly for eyelid basal cell carcinomas (BCCs).3 Ongoing studies from our group indicate that the targeted combination of cryosurgery with imiquimod is a highly efficacious modality for BCCs and Bowen's disease of the skin.4 5
This letter aims to contribute to the current discussion on imiquimod-based treatment modalities for the management of skin tumours involving eye structures.1 2 We present three patients with biopsy proven, locally advanced periocular BCCs, who refused surgery and were treated with the combination ‘cryosurgery during continuing imiquimod application’ (immunocryosurgery).4 For immunocryosurgery, a commercial imiquimod 5% cream formulation (Aldara®, MEDA) was prescribed, and the patients were instructed to apply a tiny quantity (approximately 20–30% of the sachet content) on the tumour (including an ∼0.5 cm zone of healthy skin around it) every night at bedtime and wash it with tap water the following morning. Cryosurgery was performed by the open spray liquid N2 method employing a Cry-Ac (Brymill, UK) cryogun, with a tip B, under eye surface tetracain anaesthesia. Daily imiquimod application was not interrupted—even at the evening of the day that cryosurgery was performed. We have observed that omitting daily application of …
Competing interests None to declare.
Patient consent Obtained.
Ethics approval This study was conducted with the approval of the Ethics committee Univ Hospital of Ioannina, Ioannina, Greece.
Provenance and peer review Not commissioned; externally peer reviewed.